- This event has passed.
Medications for Alcohol Use Disorder in Patients with Liver Disease: Leveraging an Underutilized Tool
June 26 @ 1:00 pm - 2:00 pm
Medications for Alcohol Use Disorder in Patients with Liver Disease: Leveraging an Underutilized Tool
June 26, 1-2 p.m. ET
Mortality due to alcohol-related liver disease (ALD) has risen steadily over the past two decades, with a sharp increase during the COVID-19 pandemic. In 2022, 46% of liver disease deaths among people ages 12 and older involved alcohol.
Despite alcohol’s role in liver disease deaths, medication treatments for alcohol use disorder (MAUD) are rarely used in patients with ALD, in part because of stigma, limited data on effectiveness, and concerns about safety and further potential damage to the liver. There is an immense opportunity to increase use of MAUD for patients with or at risk of liver disease to tackle co-occurring health needs and prevent further complications or even death.
Join us June 26, 1-2 p.m. ET for our latest PCSS-MAUD Webinar, Medications for Alcohol Use Disorder in Patients with Liver Disease: Leveraging an Underutilized Tool to learn more about why and how MAUD can be useful when working with patients living with liver disease. Hear from two hepatologists who have successfully incorporated MAUD into their respective practices, and how they are leveraging these medications to protect liver health.
Educational Objectives:
- Outline the benefits of MAUD for patients with or at risk of liver disease.
- Describe barriers to MAUD treatment for patients with or at risk of liver disease and explore ways to address these.
- Discuss safe MAUD implementation among patients with liver disease.
The webinar will feature the following speakers:
- Lamia Haque, MD, MPH, Hepatologist, Addiction Medicine Specialist, Assistant Professor of Internal Medicine, Yale School of Medicine
- Gene Im, MD, FAASLD, Transplant Hepatologist, Associate Professor of Medicine, Icahn School of Medicine